Spranger, Stefani
Ragon Institute of MGH, MIT and Harvard · Koch Institute for Integrative Cancer Research At MIT · Massachusetts Institute of Technology
11 papers on CoChatORCID 0000-0003-3257-4546
Most cited papers
- Verified
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 2,830
- Verified
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity
interferon and immune responsesImmunotherapy and Immune Responses
Cited by 1,917
- Verified
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 1,677
- Verified
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 1,539
- Verified
Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 1,441
- Verified
WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersWnt/β-catenin signaling in development and cancer
Cited by 722
- Verified
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 552
- Verified
Increased demand for NAD(+) relative to ATP drives aerobic glycolysis
Luengo, A., Li, Z., Gui, D. Y., Sullivan, L. B., Zagorulya, M., Do, B. T., Ferreira, R., Naamati, A., Ali, A., Lewis, C. A., et al. (2021) · Molecular Cell
Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer
Cited by 547
- Verified
Innate immune signaling and regulation in cancer immunotherapy
Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017) · Cell Research
Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers
Cited by 408
- Verified
Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity
Duong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., & Spranger, S. (2022) · Immunity
Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers
Cited by 372
- Verified
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
Trujillo, J. A., Luke, J. J., Zha, Y., Segal, J. P., Ritterhouse, L. L., Spranger, S., Matijevich, K., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 159
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free